30
CARDIOVASCULAR
hamburger
TactiFlex

Acute Clinical Success

TactiFlex™ Ablation Catheter, Sensor Enabled™ Acute IDE study results, data published at EHRA 2022.1

98.6% ACUTE SUCCESS

Ablation

89.6% FIRST-PASS PVI SUCCESS

Ablation

2.6% RATE OF REPEAT ABLATION IN BLANKING PERIOD

Ablation Rate

4.3% SUBJECTS WITH PRIMARY SAFETY ENDPOINT EVENT AT 90 DAYS

Safety Endpoint

SHORTER ABLATION AND PROCEDURE TIMES, LESS FLUORO AND IRRIGATION*

TOTAL PROCEDURE TIME
Total Procedure Time
TOTAL PV ABLATION TIME
Total PV Ablation Time
TOTAL FLUOROSCOPY TIME
Total Fluoroscopy Time
IRRIGATION FLUID VOLUME
Irrigation Fluid Volume

  • Manuals & Resources
    Manuals & Resources
  • Reimbursement & Coding
    Reimbursement & Coding
  • Related Products
    Related Products

This device is commercially available for use in select international markets.

*Compared to TactiCath SE in the TactiSense IDE study

References

  1. Nair, D., Martinek, M., Colley, J., et al. (2022). Acute Results of a Novel Flexible Tip Radiofrequency Catheter Incorporating Contact Force Sensing. EP Europace. 24(Supplement_1), i115-i116. https://doi.org/10.1093/europace/euac053.077

 

Indications, Safety & Warnings

MAT-2208527 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.